121 related articles for article (PubMed ID: 8639398)
21. Preoperative systemic 5-fluorouracil does not increase the risk of liver resection.
Parc Y; Dugué L; Farges O; Hiramatsu K; Sauvanet A; Belghiti J
Hepatogastroenterology; 2000; 47(36):1703-5. PubMed ID: 11149036
[TBL] [Abstract][Full Text] [Related]
22. Microsatellite instability in colon cancer.
Allegra CJ; Kim G; Kirsch IR
N Engl J Med; 2003 Oct; 349(18):1774-6; author reply 1774-6. PubMed ID: 14585950
[No Abstract] [Full Text] [Related]
23. [Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection].
Bajetta E; Cappuzzo F
Ann Ital Chir; 1996; 67(6):827-30. PubMed ID: 9214274
[TBL] [Abstract][Full Text] [Related]
24. Continuous hepatic arterial infusion chemotherapy for liver metastasis from biliary tract and pancreatic cancers.
Kato Y; Tsuyuki A; Kikuchi K; Tokuyama J; Kurihara N; Kumamoto Y; Fujishiro Y; Ebinuma H
Anticancer Res; 2005; 25(1B):477-82. PubMed ID: 15816615
[TBL] [Abstract][Full Text] [Related]
25. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
[TBL] [Abstract][Full Text] [Related]
26. Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom?
Viúdez A; Rodríguez J; Gil-Bazo I
Cardiovasc Intervent Radiol; 2009 May; 32(3):603-4. PubMed ID: 19194743
[No Abstract] [Full Text] [Related]
27. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
[TBL] [Abstract][Full Text] [Related]
28. A role for hepatic-directed chemotherapy in colorectal liver metastases.
Ensminger WD
J Clin Oncol; 2005 Aug; 23(22):4815-7. PubMed ID: 16009957
[No Abstract] [Full Text] [Related]
29. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
30. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
[TBL] [Abstract][Full Text] [Related]
31. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
32. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.
King J; Zhao J; Clingan P; Morris D
Anticancer Res; 2003; 23(1B):639-45. PubMed ID: 12680160
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant chemotherapy of colorectal cancer.
Cunningham D; Starling N
Lancet; 2007 Dec; 370(9604):1980-1. PubMed ID: 18083386
[No Abstract] [Full Text] [Related]
35. Adjuvant chemotherapy for rectal cancer.
Bujko K; Bujko M
Lancet; 2008 May; 371(9623):1502-3; author reply 1503. PubMed ID: 18456096
[No Abstract] [Full Text] [Related]
36. Mature results of adjuvant colon cancer trials from the fluorouracil-only era.
Grem JL
J Natl Cancer Inst; 2004 May; 96(10):727-9. PubMed ID: 15150295
[No Abstract] [Full Text] [Related]
37. Randomized clinical trials in advanced and metastatic colorectal carcinoma.
Dangelica MI; Shoup MC; Nissan A
Surg Oncol Clin N Am; 2002 Jan; 11(1):173-91, ix. PubMed ID: 11928799
[TBL] [Abstract][Full Text] [Related]
38. Tumour site, sex, and survival in colorectal cancer.
Rosell R; Abad A
Lancet; 2000 Sep; 356(9232):857; author reply 858. PubMed ID: 11022957
[No Abstract] [Full Text] [Related]
39. Cancers of the large bowel and hepatobiliary system.
Treat J; Ahlgren JD; Woolley PV
Cancer Chemother Biol Response Modif; 1987; 9():264-70. PubMed ID: 2856336
[No Abstract] [Full Text] [Related]
40. [Study of cut-off values for orotate phosphoribosyl transferase (OPRT) in colorectal cancer using maximal chi 2 values].
Ochiai T; Sugitani M; Nishimura K; Noguchi H; Okada T; Suda S; Kamiyama H
Nihon Geka Gakkai Zasshi; 2002 Aug; 103(8):571. PubMed ID: 12229160
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
